Молекулярно-генетические характеристики рака желудка

Молекулярно-генетические характеристики рака желудка

Автор: Шайхаев Е.Г., Лыгдынова Б.Л.

Журнал: Вестник Российского научного центра рентгенорадиологии Минздрава России @vestnik-rncrr

Рубрика: Обзоры

Статья в выпуске: 3 т.17, 2017 года.

Бесплатный доступ

Данная работа представляет собой обзор молекулярно-генетических исследований рака желудка. Отображены характеристики наследственных генетических изменений, ассоциированных с высоким риском развития заболевания. Подробно представлен молекулярно-генетический портрет опухолей желудка; описаны соматические генетические и эпигенетические характеристики, которые определяют молекулярные особенности патогенеза, а также могут выступать в качестве диагностических, прогностических и терапевтических маркеров.

Рак желудка, молекулярная генетика, онкогенетика, мутации, эпигенетические изменения

Короткий адрес: https://sciup.org/14955551

IDR: 14955551

Список литературы Молекулярно-генетические характеристики рака желудка

  • Boussioutas A., Li H., Liu J., et al. Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer. Cancer Res. 2003. V. 63. N. 10. P. 2569-2577.
  • Bumgarner R. DNA microarrays: Types, Applications and their future. Curr Protoc Mol Biol. 2013. 0 22: Unit-22.1 DOI: 10.1002/0471142727.mb2201s101
  • Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014. V. 513. N. 7517. P. 202-209.
  • Carvalho J., van Grieken N.C., Pereira P.M., et al. Lack of microRNA-101 causes Ecadherin functional deregulation through EZH2 up-regulation in intestinal gastric cancer. J Pathol. 2012. V. 228. N. 1. P. 31-44.
  • Chang H.R., Nam S., Kook M.C., et al. HNF4alpha is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer. Gut. 2016. V. 65. N. 1. P. 19-32.
  • Chia N.Y., Deng N., Das K., et al. Regulatory crosstalk between lineage-survival oncogenes KLF5, GATA4 and GATA6 cooperatively promotes gastric cancer development. Gut. 2015. V. 64. N. 5. P. 707-719.
  • Cho J.Y., Lim J.Y., Cheong J.H., et al. Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res. 2011. V. 17. P. 7. P. 1850-1857.
  • Corso G., Carvalho J., Marrelli D., et al. Somatic mutations and deletions of the Ecadherin gene predict poor survival of patients with gastric cancer. J Clin Oncol. V. 31. N. 7. P. 868-875.
  • Cristescu R., Lee J, Nebozhyn M., et al. Molecular analysis of gastric cancer identifies discrete subtypes associated with distinct clinical characteristics and survival outcomes: the ACRG (Asian Cancer Research Group) study. Nat Med. 2015. V. 21. N. 5. P. 449-456.
  • Deng N., Goh L.K., Wang H., et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut. 2012. V. 61. N. 5. V. 673-84.
  • Dulak A.M., Schumacher S.E., van Lieshout J., et al. Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res. 2012. V. 72. N. 17. P. 4383-4393.
  • Edwards P.A. Fusion genes and chromosome translocations in the common epithelial cancers. J Pathol. 2010. V. 220. N. 2. P. 244-254.
  • El-Omar E.M., Carrington M., Chow W.H., et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000. V. 404. N. 6776. P. 398-402.
  • Ferlay J., Soerjomataram I., Dikshit R., Eser S., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 V.136. N. 5. P. 359-386.
  • Figueiredo C., Machado J.C., Pharoah P., et al. Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst. 2002. V. 94. N. 22. P. 1680-1687.
  • Ganesan K., Ivanova T., Wu Y., et al. Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene. Cancer Res. 2008.V. 68. N. 11. P. 4277-4286.
  • Giacomini C.P., Sun S., Varma S., et al. Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types. PLoS Genet. 2013. V. 9. N. 4. e1003464.
  • Hanazono K., Natsugoe S., Stein H.J., et al. Distribution of p53 mutations in esophageal and gastric carcinomas and the relationship with p53 expression. Oncol Rep. 2006.V. 15. N. 4. P. 821-824.
  • Hansford S., Kaurah P., Li-Chang H., et al. Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. JAMA Oncol. 2015. V. 1. N. 1. P. 23-32.
  • Haveri H., Westerholm-Ormio M., Lindfors K., et al. Transcription factors GATA-4 and GATA-6 in normal and neoplastic human gastrointestinal mucosa. BMC Gastroenterol. 2008:8:9 DOI: 10.1186/1471-230X-8-9
  • Huntsman D.G., Carneiro F., Lewis F.R., et al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med. 2001. V. 344. N. 25. P. 1904-1909.
  • Ishimoto T, Nagano O, Yae T, et al. CD44 variant regulates redox status in Cancer Cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell. 2011. V. 19. N. 3. P. 387-400.
  • Kakiuchi M, Nishizawa T, Ueda H, et al. Recurrent gainof-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet. 2014. V. 46. P.583-587.
  • Kim J., Fox C., Peng S., et al. Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. J Clin Invest. 2014. V. 124. N. 12. P. 5145-5158.
  • Kim T.M., Jung S.H., Kim M.S., et al. The mutational burdens and evolutionary ages of early gastric cancers are comparable to those of advanced gastric cancers. J Pathol. 2014. V. 234. N. 3. P. 365-374.
  • Kim Y.H., Liang H., Liu X., et al. AMPK alpha modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer. Cancer Res. 2017. V. 77. N. 9. P. 2512-2521.
  • Lan F., Shi Y. Epigenetic regulation: methylation of histone and non-histone proteins. Sci China C Life Sci. 2009. V. 52. N. 4. P. 311-322.
  • Lau W.M., Teng E., Chong H.S., et al. CD44v8-10 is a cancer-specific marker for gastric cancer stem cells. Cancer Res. 2014. V. 74. N. 9. P. 2630-2641.
  • Lawrence M.S., Stojanov P., Polak P., et al. Mutational heterogeneity in cancer and the search for new cancer associated genes. Nature. 2013. V. 499. N. 7457. P. 214-218.
  • Lee J., Lee S.E., Kang S.Y., et al. Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer. 2013. V. 119. N. 9. P. 1627-1635.
  • Lee J., Sohn I., Do I.G., et al. Nanostring-based multigene assay to predict recurrence for gastric cancer patients after surgery. PLoS One. 2014 V. 9. N. 3. e90133.
  • Liu X., Chu K.M. E-cadherin and gastric cancer: cause, consequence, and applications. Biomed Res Int. 2014: 637308 DOI: 10.1155/2014/637308
  • Lochhead P., El-Omar E.M. Gastric cancer. Br Med Bull. 2008. V. 85. P. 87-100.
  • Matsusaka K., Kaneda A., Nagae G., et al. Classification of Epstein-Barr virus-positive gastric cancers by definition of DNA methylation epigenotypes. Cancer Res. 2011. V. 71. N. 23. P. 7187-97.
  • Muratani M., Deng N., Ooi W.F., et al. Nanoscale chromatin profiling of gastric adenocarcinoma reveals cancer associated cryptic promoters and somatically acquired regulatory elements. Nat Commun. 2014. 5:4361 DOI: 10.1038/ncomms5361
  • Nagarajan N., Bertrand D., Hillmer A.M., et al. Whole genome reconstruction and mutational signatures in gastric cancer. Genome Biol. 2012. V. 13. N. P.115. R115 DOI: 10.1186/gb-2012-13-12-r115
  • Nakamura J., Tanaka T., Kitajima Y., et al. Methylationmediated gene silencing as biomarkers of gastric cancer: a review. World J Gastroenterol. 2014. V. 20. N. 34. P. 11991-12006.
  • Noto J.M., Gaddy J.A., Lee J.Y., et al. Iron deficiency accelerates Helicobacter pylori-induced carcinogenesis in rodents and humans. J Clin Invest. 2013. V. 123. N. 1. P. 479-492.
  • Ohtsu A., Shah M.A., Van Cutsem E., et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011. V. 29. N. 30. P. 3968-76.
  • Oliveira C., Pinheiro H., Figueiredo J., et al. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncol. 2015 V. 16. N. 2. P. 60-70.
  • Ooi C.H., Ivanova T., Wu J., et al. Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS Genet. 2009. V. 5. N. 10:e1000676.
  • Palanisamy N., Ateeq B., Kalyana-Sundaram S., et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med. 2010. V. 16. P. 793-798.
  • Persson C., Canedo P., Machado J.C., et al. Polymorphisms in inflammatory response genes and their association with gastric cancer: A HuGE systematic review and meta-analyses. Am J Epidemiol. 2011. V. 173. N. P. 259-70.
  • Polakis P. Wnt signaling in cancer. Cold Spring Harb Perspect Biol. 2012. V. 4. N. 5. a008052.
  • Qian J., Kong X., Deng N., et al. OCT1 is a determinant of synbindin-related ERK signalling with independent prognostic significance in gastric cancer. Gut. 2015. V. 64. N. 1. P.37-48.
  • Scaltriti M., Eichhorn P.J., Cortes J., et al. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2þ breast cancer patients. Proc Natl Acad Sci U S A. 2011. V. 108. N. 9. P. 3761-3766.
  • Sulahian R., Casey F., Shen J., et al. An integrative analysis reveals functional targets of GATA6 transcriptional regulation in gastric cancer. Oncogene. 2014. V. 33. N. 49. P. 5637-5648.
  • Takahashi N., Yamada Y., Taniguchi H., et al. Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer. BMC Res Notes. 2014. 7:271 DOI: 10.1186/1756-0500-7-271
  • Takeshima H., Niwa T., Takahashi T., et al. Frequent involvement of chromatin remodeler alterations in gastric field cancerization. Cancer Lett. 2015. V. 357. N. 1. P. 328-338.
  • Tan I.B., Ivanova T., Lim K.H., et al. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology. 2011 V. 14. N. 2. P. 476-85.
  • Tan P., Yeoh K.G. Genetics and Molecular Pathogenesis of Gastric Adenocarcinoma. Gastroenterology. 2015. V. 149. N. 5. P. 1153-1162.
  • Tao J., Deng N.T., Ramnarayanan K., et al. CD44-SLC1A2 gene fusions in gastric cancer. Sci Transl Med. 2011. V. 3. N. 77. 77ra30.
  • Toyota M., Ahuja N., Suzuki H., et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res. 1999. V. 59. N. 21. P. 5438-5442.
  • Tsugane S., Sasazuki S. Diet and the risk of Gastric Cancer: review of epidemiological evidence. Gastric Cancer. 2007. V. 10. N. 2. P. 75-83.
  • Wang K., Kan J., Yuen S.T., et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet. 2011. V. 43. N.12 P. 1219-1223.
  • Wang K., Yuen S.T., Xu J., et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet. 2014. V. 46. N. 6. P. 573-582.
  • Wang L., Xie L., Wang J., et al. Correlation between the methylation of SULF2 and WRN promoter and the irinotecan chemosensitivity in gastric cancer. BMC Gastroenterol. 2013;13:173.
  • Wang Y., Liu J., Huang B.O., et al. Mechanism of alternative splicing and its regulation. Biomed Rep. 2015. V. 3. N. 2. P. 152-158.
  • Wong S.S., Kim K.M., Ting J.C., et al. Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing. Nat Commun. 2014. V. 19. N. 5:5477 DOI: 10.1038/ncomms6477
  • Worthley DL, Phillips KD, Wayte N, et al. Gastric adenocarcinoma and proximal polyposis of the stomach(GAPPS): a new autosomal dominant syndrome. Gut. 2012. V. 61. N. 5. P. 774-779.
  • Yan C., Higgins P.J. Drugging the undruggable: transcription therapy for cancer. Biochim Biophys Acta. 2013. V. 1835. N. 1. P. 76-85.
  • Yao F., Kausalya J.P., Sia Y.Y., et al. Recurrent fusion genes in gastric cancer: CLDN18-ARHGAP26 induces loss of epithelial integrity. Cell Rep. 2015. V. 12. N. 2. P. 272-85.
  • Zang Z.J., Cutcutache I., Poon S.L., et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet. 2012. V. 44. N. 5. P. 570-574.
  • Zhang L., Zhong K., Dai Y., et al. Genome-wide analysis of histone H3 lysine 27 trimethylation by ChIP-chip in gastric cancer patients. J Gastroenterol. 2009. V. 44. N. 4. P. 305-312.
  • Zouridis H., Deng N., Ivanova T., et al. Methylation subtypes and large-scale epigenetic alterations in gastric cancer. Sci Transl Med. 2012. V. 4. N. 156. 156ra140.
Еще
Статья научная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp